Table 3.
Proportions of patients with normal functioning before and after treatment.
| Level* | N | Within normal functioning entry (%) | Within normal functioning exit (%) | McNemar test p value |
|---|---|---|---|---|
| 1 | 2280 | 6.7 | 38.5 | <0.0001 |
| 2 | 749 | 6.4 | 31.9 | <0.0001 |
| 3 | 190 | 4.7 | 16.8 | <0.0001 |
| 4 | 56 | 1.8 | 16 | 0.022 |
| 12-month f/u | 414 | 60.1 | 49.0 | <0.0001 |
‘Functioning within normal’ is defined as WSAS scores of less than 10 [Mundt et al. 2002]. Levels of treatment are as follows. Level 1: citalopram monotherapy; level 2: switching to sertraline, sustained release (SR) bupropion, extended release (XR) venlafaxine, or cognitive behavioral therapy (CBT); or augmenting with bupropion SR, buspirone; or CBT; level 3: switching to nortriptyline or mirtazapine; or augmenting with lithium or triiodothyronine (T3); level 4: switching to tranylcypromine; or switching to venlafaxine XR plus mirtazapine.
*
Values compared between entry and exit at each level and between entry to follow up and exit at 12 months of follow up.